New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions

Dermatology

Volumn 233, Issue 1, 2017, Pages 37-46

  Li, Jiang ^a,c   Liu, Lei ^b,c   Rui, Wenlong ^b   Li, Xiangyu ^b   Xuan, Dandan ^b,c   Zheng, Shucong ^b,c   Yu, Yiyun ^b,c   Zhang, Jiong ^b,c   Kong, Ning ^b,c   Zhu, Xiaoxia ^b,c   Zou, Hejian ^b,c   Wan, Weiguo ^b,c   Xue, Yu ^b,c  

^a LINYI PEOPLE'S HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Bath Ankylosing Spondylitis Radiology Index; Interleukins; Osteoclast precursors; Psoriasis; Psoriasis Area and Severity Index; Psoriatic arthritis; Psoriatic Arthritis Joint Activity Index; Sharp score

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 33; INTERLEUKIN 34; INTERLEUKIN 35; INTERLEUKIN 36; INTERLEUKIN 37; INTERLEUKIN 38; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; BONE EROSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS JOINT ACTIVITY INDEX; SKIN DISEASE ASSESSMENT;

EID: 85021729602     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000471798     Document Type: Article

References (40)

1. Kang EJ, Kavanaugh A: Psoriatic arthritis: latest treatments and their place in therapy.Ther Adv Chronic Dis 2015; 6: 194-203.
2. Duan L, Chen J, Gong F, Shi G: The role of IL-33 in rheumatic diseases.Clin Dev Immunol 2013; 2013: 924363.
3. Li Y, Wang Y, Liu Y, Wang Y, Zuo X, Li Y, et al: The possible role of the novel cytokines IL-35 and IL-37 in inflammatory bowel disease.Mediators Inflamm 2014; 2014: 136329.
4. Ye L, Jiang B, Deng J, Du J, Xiong W, Guan Y, et al: IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation.J Immunol 2015; 194: 5110-5119.
5. Boutet MA, Bart G, Penhoat M, Amiaud J, Brulin B, Charrier C, et al: Distinct Expression of interleukin (IL)-36, and , their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.Clin Exp Immunol 2016; 184: 159-173.
6. Kocijan R, Englbrecht M, Haschka J, Simon D, Kleyer A, Finzel S, et al: Quantitative and qualitative changes of bone in psoriasis and psoriatic arthritis patients.J Bone Miner Res 2015; 30: 1775-1783.
7. Taylor WJ, Porter GG, Helliwell PS: Operational definitions and observer reliability of the plain radiographic features of psoriatic arthritis.J Rheumatol 2003; 30: 2645-2658.
8. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation.Nature 2003; 423: 337-342.
9. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM: Mechanisms of TNF-alpha-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.J Clin Invest 2003; 111: 821-831.
10. Wada T, Nakashima T, Hiroshi N, Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone disease.Trends Mol Med 2006; 12: 17-25.
11. Xue Y, Jiang L, Cheng Q, Chen H, Yu Y, Lin Y, et al: Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions.PLoS One 2012; 7:e46740.
12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al: Classification criteria for psoriatic arthritis: development of new criteria from a large international study.Arthritis Rheum 2006; 54: 2665-2673.
13. Rzany B, Naldi L, Schafer T, Stern R, Williams H: The diagnosis of psoriasis: diagnostic criteria.Br J Dermatol 1998; 138: 917.
14. Gladman DD, Tom BD, Mease PJ, Farewell VT: Informing response criteria for psoriatic arthritis (PsA).II: further considerations and a proposal-the PsA joint activity index.J Rheumatol 2010; 37: 2559-2565.
15. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, et al: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2.Arthritis Rheum 2007; 56: 2698-2707.
16. Calin A, Mackay K, Santos H, Brophy S: A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index.J Rheumatol 1999; 26: 988-992.
17. MacKay K, Mack C, Brophy S, Calin A: The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment.Arthritis Rheum 1998; 41: 2263-2270.
18. Alunno A, Carubbi F, Cafaro G, Pucci G, Battista F, Bartoloni E, et al: Targeting the IL-23/ IL-17 axis for the treatment of psoriasis and psoriatic arthritis.Expert Opin Biol Ther 2015; 15: 1727-1737.
19. Maruotti N, Grano M, Colucci S, d'Onofrio F, Cantatore FP: Osteoclastogenesis and arthritis.Clin Exp Med 2011; 11: 137-145.
20. Kanda N, Watanabe S: IL-12, IL-23, and IL-27 enhance human beta-defensin-2 production in human keratinocytes.Eur J Immunol 2008; 38: 1287-1296.
21. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-Duculan J, et al: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.J Exp Med 2007; 204: 3183-3194.
22. Mitsui A, Tada Y, Takahashi T, Shibata S, Kamata M, Miyagaki T, et al: Serum IL-33 levels are increased in patients with psoriasis.Clin Exp Dermatol 2016; 41: 183-189.
23. Chen Z, Buki K, Vaaraniemi J, Gu G, Vaananen HK: The critical role of IL-34 in osteoclastogenesis.PLoS One 2011; 6:e18689.
24. Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, et al: Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.J Pathol 2010; 221: 77-86.
25. Hwang SJ, Choi B, Kang SS, Chang JH, Kim YG, Chung YH, et al: Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis.Arthritis Res Ther 2012; 14:R14.
26. Chemel M, Le Goff B, Brion R, Cozic C, Berreur M, Amiaud J, et al: Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients.Ann Rheum Dis 2012; 71: 150-154.
27. Li Y, Li D, Li Y, Wu S, Jiang S, Lin T, et al: Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes.Osteoporos Int 2016; 27: 1537-1546.
28. Clavel G, Thiolat A, Boissier MC: Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38.Joint Bone Spine 2013; 80: 449-453.
29. Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N, et al: Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation.J Exp Med 2007; 204: 2603-2614.
30. Blumberg H, Dinh H, Dean C Jr, Trueblood ES, Bailey K, Shows D, et al: IL-1RL2 and its ligands contribute to the cytokine network in psoriasis.J Immunol 2010; 185: 4354-4362.
31. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al: Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis.N Engl J Med 2011; 365: 620-628.
32. Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, et al: Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis.Am J Hum Genet 2011; 89: 432-437.
33. Sugiura K, Takeichi T, Kono M, Ogawa Y, Shimoyama Y, Muro Y, et al: A novel IL36RN/IL1F5 homozygous nonsense mutation, p.Arg10X, in a Japanese patient with adult-onset generalized pustular psoriasis.Br J Dermatol 2012; 167: 699-701.
34. Frey S, Derer A, Messbacher ME, Baeten DL, Bugatti S, Montecucco C, et al: The novel cytokine interleukin-36 is expressed in psoriatic and rheumatoid arthritis synovium.Ann Rheum Dis 2013; 72: 1569-1574.
35. Magne D, Palmer G, Barton JL, Mezin F, Talabot-Ayer D, Bas S, et al: The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes.Arthritis Res Ther 2006; 8:R80.
36. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA: IL-37 is a fundamental inhibitor of innate immunity.Nat Immunol 2010; 11: 1014-1022.
37. Keermann M, Koks S, Reimann E, Abram K, Erm T, Silm H, et al: Expression of IL-36 family cytokines and IL-37 but not IL-38 is altered in psoriatic skin.J Dermatol Sci 2015; 80: 150-152.
38. Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace AM, et al: Cloning and characterization of IL-1HY2, a novel interleukin-1 family member.J Biol Chem 2001; 276: 20597-20602.
39. Rahman P, Sun S, Peddle L, Snelgrove T, Melay W, Greenwood C, et al: Association between the interleukin-1 family gene cluster and psoriatic arthritis.Arthritis Rheum 2006; 54: 2321-2325.
40. Wu Z, Gu JR: A meta-analysis on interleukin-1 gene cluster polymorphism and genetic susceptibility for ankylosing spondylitis.Zhonghua Yi Xue Za Zhi 2007; 87: 433-437.